Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery Article (Faculty180)

cited authors

  • Gorin, Mich A; Ekwenna, Obi; Soloway, Mark S; Ciancio, Gaetano


  • Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.


publication date

  • 2012

published in

start page

  • e11


  • 79